Tianyu pharmaceutical industry strives to build a competitive pharmaceutical enterprise

[China Pharmaceutical network enterprise news] recently, Zhejiang Tianyu Pharmaceutical Co., Ltd (hereinafter referred to as "Tianyu pharmaceutical") disclosed and updated the prospectus The company plans to issue no more than 120 million shares in the gem, and plans to raise 674 million yuan The sponsor of this IPO is CSC securities (picture source: Baidu picture) according to the data, Tianyu pharmaceutical is a company mainly engaged in the research and development, production and sales of chemical APIs and intermediates, which can be divided into non CMO business of APIs and intermediates and CMO business of APIs and intermediates according to business types Tianyu Pharmaceutical Co., Ltd introduced that since its establishment, the company has always adhered to the concept of "refining, refining and strengthening" products and enterprises with continuous technological innovation, and put the product registration and certification ability and the ability to serve customers first In the future, the company will optimize and upgrade the product structure, continue to increase the sales proportion of API, continue to strengthen and expand the API and intermediate business, continue to enhance the core competitiveness of API, and further consolidate and enhance the position of the company as an important API supplier of global Shatin drugs   At the same time, Tianyu pharmaceutical arranges the R & D and application and registration plan of related APIs according to the drug expiration time, speeds up the acquisition of drug registration number, ensures that the company can register 3-5 new API varieties every year, strengthens the advantages of the company's quality management and qualification certification, improves the company's core competitiveness and international level, and ensures that the company's API and intermediate manufacturing business is further improved Growth In addition, Tianyu pharmaceutical continues to consolidate and strengthen the cooperation between API products and domestic and foreign pharmaceutical manufacturers and distributors, further consolidate the basis of cooperation with original pharmaceutical manufacturers and international generic giants, seek deeper cooperation in product R & D and production, and promote the rapid growth of API and CMO business of the company Tianyu pharmaceutical said that in the future, it will vigorously introduce domestic and foreign talents, consolidate the high-quality talent team to meet the overall requirements of international development, strengthen the internal system management mechanism, and promote the normal operation of enterprises according to the advanced management system Tianyu pharmaceutical will continue to accelerate the pace of industrial upgrading, expand and improve the non CMO business and CMO business of APIs and intermediates, continue to improve the internal and external R & D systems and two sales systems of the company, continue to promote the research and development of preparations, further promote and deepen the international development strategy, fully integrate into the international pharmaceutical industry chain, and strive to build domestic and international knowledge Famous and competitive pharmaceutical enterprises.